Related Experiment Video

Updated: Sep 15, 2025

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

15.2K

Discovery of Natural Compound α-Hederin via Large-Scale Screening as a Targeted JAK/STAT3 Inhibitor for Ovarian

Jiayu Wang1, Pengzhan He2, Cheng Liu3

  • 1Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|July 16, 2025
PubMed

Insights

α-Hederin, a natural compound, effectively inhibits ovarian cancer progression by targeting JAK1/JAK2 and STAT3 signaling. It shows promise in overcoming chemoresistance and metastasis, with potential for clinical use.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Chemoresistance and metastasis are significant challenges in ovarian cancer (OC) treatment.
  • Targeting key signaling pathways like JAK/STAT3 offers therapeutic potential for OC.

Purpose of the Study:

  • To investigate α-Hederin as a dual inhibitor of JAK1/JAK2 for ovarian cancer treatment.
  • To elucidate the mechanism of action of α-Hederin in suppressing OC progression.

Main Methods:

  • Transcriptomic analysis, virtual screening, molecular docking, and biochemical validation were employed.
  • In vitro and in vivo studies in mouse models assessed α-Hederin's efficacy and toxicity.
  • Mechanism of action explored via STAT3 phosphorylation, nuclear translocation, and target gene analysis.

Main Results:

  • α-Hederin selectively inhibits JAK1/JAK2, suppressing STAT3 phosphorylation and downstream oncogenic targets (MYC, CCND1, TWIST1).
  • α-Hederin demonstrated significant inhibition of OC cell proliferation, epithelial-mesenchymal transition (EMT), and metastasis in vitro and in vivo.
  • The compound exhibited minimal systemic toxicity and synergized with cisplatin, overcoming platinum resistance.

Conclusions:

  • α-Hederin is a potent and safe natural JAK1/2 inhibitor targeting the JAK/STAT3 pathway in ovarian cancer.
  • It effectively suppresses tumor growth, metastasis, and chemoresistance, representing a promising candidate for clinical translation.
Keywords:
JAKmetastasisovarian cancerproliferationα‐Hederin

More Related Videos

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity09:59

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

1.2K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K